Maintenance interleukin-2 (IL-2) and sargramostim (GM-CSF) following high-dose IL-2 (HD IL-2) therapy for metastatic melanoma.
Melinda Bernabe Chu
No relevant relationships to disclose
Mark Fesler
No relevant relationships to disclose
Eric Armbrecht
No relevant relationships to disclose
Scott Fosko
No relevant relationships to disclose
Eddy C. Hsueh
No relevant relationships to disclose
John M. Richart
No relevant relationships to disclose